期刊文献+

西黄胶囊联合复方苦参注射液辅助治疗结肠癌的临床研究 被引量:5

Clinical trial of Xihuang capsules combined with compound matrine injection in the adjuvant treatment of colon cancer
原文传递
导出
摘要 目的观察西黄胶囊联合复方苦参注射液辅助治疗结肠癌的临床疗效及安全性。方法将52例结肠癌术后患者随机分为对照组26例及试验组26例。对照组予以复方苦参注射液2 mL,qd,静脉滴注;试验组在对照组治疗的基础上,予以西黄胶囊每次2.0 g,bid,口服。2组患者均治疗56 d。比较2组患者的临床疗效、CD_3^+、CD_4^+、CD_8^+T淋巴细胞水平、CD_4^+/CD_8^+比值,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为53.85%(14/26例)和26.92%(7/26例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的CD_3^+分别为(66.08±8.11)%和(54.36±6.94)%,CD_4^+分别为(46.16±5.32)%和(25.46±3.16)%,CD_8^+分别为(23.26±3.14)%和(30.57±4.28)%,CD_4^+/CD_8^+分别为(1.98±0.26)和(0.83±0.11),差异均有统计学意义(均P<0.05)。2组患者的药物不良反应主要有白细胞减少、恶心呕吐、肝肾功能异常、血小板减少,且试验组和对照组的药物不良反应发生率分别为46.16%和76.92%,差异有统计学意义(P<0.05)。结论西黄胶囊联合复方苦参注射液辅助治疗结肠癌的临床疗效显著,其能够明显减轻患者免疫功能的损伤,减少化疗相关的药物不良反应。 Objective To observe the clinical efficacy and safety of Xi- huang capsules combined with compound matrine injection in the adju- vant treatment of colon cancer. Methods Fifty - two patients after colon cancer surgery were randomly divided into control group and treatment group with 26 cases per group. Control group was given compound ma- trine injection 2 mL, qd, intravenous drip. Treatment group was given Xihuang capsules 2. 0 g, bid, oral, on the basis of the control group. Two groups were treated for 56 d. The clinical efficacy, the levels of CD3, CD4+, CDs T lymphocytes, CD4+/CDs+ ratio and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates in the treatment and control groups were 53.85% ( 14/26 cases) and 26. 92% ( 7/26 cases) with significant difference (P 〈 0. 05 ). After treatment, the main indexes in treatment and control groups were compared: CD3 ± were ( 66. 08 ± 8. 11 ) %, ( 54. 36 ± 6. 94) % ; CD4+ were (46.16± 5. 32)%, (25.46 ± 3. 16)%; CD8+ were (23.26 ±3.14)%, (30. 57 ±4. 28)% ; CD4+/CD8+ were (1.98 ±0.26),(0. 83 + 0. 11 ), the differences were statistically significant ( all P 〈 0.05 ). The adverse drug reactions in two groups were based on leukopenia, nausea and vomiting, liver and kidney dysfunction and thrombocytopenia. The incidences of adverse drug reactions in treatment and control groups were 46. 15% and 76. 92% with significant difference (P 〈0.05). Conclusion The combination of Xihuang capsules and compound matrine injection has a definitive clinical efficacy in the adjuvant treatment of colon cancer, which can significantly reduce the damage of the immune function of patients and chemotherapy - related adverse drug reactions.
作者 阎立凯
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2017年第16期1543-1545,共3页 The Chinese Journal of Clinical Pharmacology
基金 河南省医学科技攻关计划基金资助项目(201203047)
关键词 西黄胶囊 复方苦参注射液 结肠癌 安全性 Xihuang capsule compound matrine injection colon cancer safety
  • 引文网络
  • 相关文献

参考文献4

二级参考文献47

  • 1何立丽,孙桂芝.孙桂芝教授治疗大肠癌经验[J].辽宁中医药大学学报,2009,11(4):97-99. 被引量:30
  • 2陈智伟,廖美琳,陈玉蓉,赵家美,张心敏,成柏君.WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学,2004,4(2):83-84. 被引量:34
  • 3Figueredo A,Coombes ME,Mukherjee S. Adjuvant therapy for completely resected stage lI colon cancer. Cochrane Database of systematic reviews [J]. 2008,16(3 ) : CD005390.
  • 4Denis F,Garaud P,Bardet E,et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant ra- diochemotherapy for advanced-stage oropharynx carcinoma:comparison of LENT/SOMA,RTOG/EORTC,and NCI-CTC scoring systems [J]. Int J Radiat Oncol Biol Phys, 2003,55 ( 1 ) : 93-98.
  • 5Ota D,Nelson H. The surgeon and adjuvant therapy for stage lI colon cancer [J]. Annals of Surgical Oncology, 2007,14 (2) : 272-273.
  • 6Hailer D,Tabernero J,Maroun J,et al. First efficacy findings from a randomized phase 1II trial of capecitabine+oxaliplat in versus bolus 5- FU/LV for stage m colon cancer (NO 16968/XELOXA study [J]. Euro- pean Journal of Cancer Supplements, 2009,7 ( 1 ) :4.
  • 7Cassidy J,Scheithauer W, McKendrick J,et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study) :efficacy results of a phase IH trial [J]. J Clin 0ncol,2004,22 (14S) :247.
  • 8de-Gramont A,Boni C ,Navarro M,et al. Oxaliplatin/5-FU/LV in adju- vant colon cancer:updated efficacy results of the MOSAIC trial.in- cluding survival,with a median follow-up of 6 years [J]. Proc Am Soc Clin Oneo1,2007,25 (18) : 165s.
  • 9蔡光先.肿瘤特色方药[M].北京:人民卫生出版社,2006.579.
  • 10刘磊磊,陈娟,师彦平.清热解毒中药抗肿瘤作用研究进展[J],2012,43(6):1203-1212.

共引文献1609

同被引文献69

引证文献5

二级引证文献53

相关主题

;
使用帮助 返回顶部